Critical Review: TherapeuticsMD (TXMD) vs. Its Competitors
TherapeuticsMD (NASDAQ: TXMD) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare TherapeuticsMD to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.
Volatility and Risk
TherapeuticsMD has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, TherapeuticsMD’s competitors have a beta of 0.89, meaning that their average share price is 11% less volatile than the S&P 500.
This is a summary of recent recommendations for TherapeuticsMD and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TherapeuticsMD presently has a consensus target price of $14.88, indicating a potential upside of 209.90%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 23.19%. Given TherapeuticsMD’s stronger consensus rating and higher possible upside, equities research analysts clearly believe TherapeuticsMD is more favorable than its competitors.
Insider and Institutional Ownership
71.6% of TherapeuticsMD shares are held by institutional investors. Comparatively, 66.8% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 23.9% of TherapeuticsMD shares are held by company insiders. Comparatively, 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares TherapeuticsMD and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares TherapeuticsMD and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|TherapeuticsMD||$18.26 million||-$88.99 million||-10.43|
|TherapeuticsMD Competitors||$2.40 billion||$905.93 million||-0.10|
TherapeuticsMD’s competitors have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
TherapeuticsMD beats its competitors on 7 of the 12 factors compared.
TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.